Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.

NCT02292745 is registered in ClinicalTrials.gov with Foundation for Liver Research as lead sponsor.

NCT NCT02292745
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02292745 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.
Lead sponsor
Foundation for Liver Research
Phase
Not applicable
Overall status
Completed
Start date
December 2, 2014
Completion date
May 24, 2018
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms